Skip to main content

Books in Drug discovery

Elsevier's Drug Delivery collection is an indispensable resource for scientists and researchers in the pharmaceutical field, exploring the administration of pharmaceutical compounds for therapeutic effects from molecule identification to medication development. It provides comprehensive coverage, including crucial aspects such as drug screening, medicinal chemistry, and preclinical safety assessments.

51-60 of 69 results in All results

Single Molecule Biology

  • 1st Edition
  • October 29, 2008
  • Alexander E. Knight
  • English
  • Hardback
    9 7 8 - 0 - 1 2 - 3 7 4 2 2 7 - 8
  • eBook
    9 7 8 - 0 - 0 8 - 0 9 2 1 2 3 - 5
Single molecule techniques, including single molecule fluorescence, optical tweezers, and scanning probe microscopy, allow for the manipulation and measurement of single biological molecules within a live cell or in culture. These approaches, amongst the most exciting tools available in biology today, offer powerful new ways to elucidate biological function, both in terms of revealing mechanisms of action on a molecular level as well as tracking the behaviour of molecules in living cells. This book provides the first complete and authoritative treatment of this rapidly emerging field, explicitly from a biological perspective.The contents are organized by biological system or molecule. Each chapter discusses insights that have been revealed about their mechanism, structure or function by single molecule techniques. Among the topics covered are enzymes, motor proteins, membrane channels, DNA, ribozymes, cytoskeletal proteins, and other key molecules of current interest. An introduction by the editor provides a concise review of key principles and an historical overview. The last section discusses applications in molecular diagnostics and drug discovery.

Animal and Translational Models for CNS Drug Discovery: Neurological Disorders

  • 1st Edition
  • October 6, 2008
  • Robert A. McArthur + 1 more
  • English
  • Hardback
    9 7 8 - 0 - 1 2 - 3 7 3 8 5 5 - 4
  • eBook
    9 7 8 - 0 - 0 8 - 0 9 2 0 3 8 - 2
Neurological Disorders is written for researchers in both academia and the pharmaceutical industry who use animal models in research and development of drugs for neurological disorders such as neurofibromatosis, Alzheimer’s disease, Parkinson’s disease, Huntington disease, ALS, and the epilepsies. Neurological Disorders has introductory chapters expressing the view of the role and relevance of animal models for drug discovery and development for the treatment of psychiatric disorders from the perspective of (a) academic basic neuroscientific research, (b) applied pharmaceutical drug discovery and development, and (c) issues of clinical trial design and regulatory agencies limitations. Each volume examines the rationale, use, robustness and limitations of animal models in each therapeutic area covered and discuss the use of animal models for target identification and validation. The clinical relevance of animal models is discussed in terms of major limitations in cross-species comparisons, clinical trial design of drug candidates, and how clinical trial endpoints could be improved. The aim of this series of volumes on Animal and Translational Models for CNS Drug Discovery is to identify and provide common endpoints between species that can serve to inform both the clinic and the bench with the information needed to accelerate clinically-effective CNS drug discovery. This is the second volume in the three volume-set, Animal and Translational Models for CNS Drug Discovery 978-0-12-373861-5, which is also available for purchase individually.

Animal and Translational Models for CNS Drug Discovery: Psychiatric Disorders

  • 1st Edition
  • October 6, 2008
  • Robert A. McArthur + 1 more
  • English
  • Hardback
    9 7 8 - 0 - 1 2 - 3 7 3 8 5 6 - 1
  • eBook
    9 7 8 - 0 - 0 8 - 0 9 2 0 3 9 - 9
Psychiatric Disorders is written for researchers in both academia and the pharmaceutical industry who use animal models in research and development of drugs for psychiatric disorders such as anxiety, obsessive-compulsive disorder, depression, schizophrenia, bipolar disorder, ADHD, and autistic spectrum disorder. Psychiatric Disorders has introductory chapters expressing the view of the role and relevance of animal models for drug discovery and development for the treatment of psychiatric disorders from the perspective of (a) academic basic neuroscientific research, (b) applied pharmaceutical drug discovery and development, and (c) issues of clinical trial design and regulatory agencies limitations. Each volume examines the rationale, use, robustness and limitations of animal models in each therapeutic area covered and discuss the use of animal models for target identification and validation. The clinical relevance of animal models is discussed in terms of major limitations in cross-species comparisons, clinical trial design of drug candidates, and how clinical trial endpoints could be improved. The aim of this series of volumes on Animal and Translational Models for CNS Drug Discovery is to identify and provide common endpoints between species that can serve to inform both the clinic and the bench with the information needed to accelerate clinically-effective CNS drug discovery. This is the first volume in the three volume-set, Animal and Translational Models for CNS Drug Discovery 978-0-12-373861-5, and is also available for purchase individually.

Animal and Translational Models for CNS Drug Discovery: Reward Deficit Disorders

  • 1st Edition
  • October 6, 2008
  • Robert A. McArthur + 1 more
  • English
  • Hardback
    9 7 8 - 0 - 1 2 - 3 7 3 8 6 0 - 8
  • eBook
    9 7 8 - 0 - 0 8 - 0 9 2 0 4 0 - 5
Reward Deficit Disorders is written for researchers in both academia and the pharmaceutical industry who use animal models in research and development of drugs for reward deficit disorders such as alcohol dependence, nicotine dependence, heroin and cocaine addiction, obesity, and gambling and impulse control disorders. Reward Deficit Disorders has introductory chapters expressing the view of the role and relevance of animal models for drug discovery and development for the treatment of psychiatric disorders from the perspective of (a) academic basic neuroscientific research, (b) applied pharmaceutical drug discovery and development, and (c) issues of clinical trial design and regulatory agencies limitations. Each volume examines the rationale, use, robustness and limitations of animal models in each therapeutic area covered and discuss the use of animal models for target identification and validation. The clinical relevance of animal models is discussed in terms of major limitations in cross-species comparisons, clinical trial design of drug candidates, and how clinical trial endpoints could be improved. Reward Deficit Disorders also has a section dedicated to the specifics of the regulatory aspects to abuse liability testing. The aim of this series of volumes on Animal and Translational Models for CNS Drug Discovery is to identify and provide common endpoints between species that can serve to inform both the clinic and the bench with the information needed to accelerate clinically-effective CNS drug discovery. This is the third volume in the three volume-set, Animal and Translational Models for CNS Drug Discovery 978-0-12-373861-5, which is also available for purchase individually.

The Practice of Medicinal Chemistry

  • 3rd Edition
  • July 24, 2008
  • Camille Georges Wermuth
  • English
  • eBook
    9 7 8 - 0 - 0 8 - 0 5 6 8 7 7 - 5
The Practice of Medicinal Chemistry fills a gap in the list of available medicinal chemistry literature. It is a single-volume source on the practical aspects of medicinal chemistry. Considered ""the Bible"" by medicinal chemists, the book emphasizes the methods that chemists use to conduct their research and design new drug entities. It serves as a practical handbook about the drug discovery process, from conception of the molecules to drug production. The first part of the book covers the background of the subject matter, which includes the definition and history of medicinal chemistry, the measurement of biological activities, and the main phases of drug activity. The second part of the book presents the road to discovering a new lead compound and creating a working hypothesis. The main parts of the book discuss the optimization of the lead compound in terms of potency, selectivity, and safety. The Practice of Medicinal Chemistry can be considered a ""first-read"" or ""bedside book"" for readers who are embarking on a career in medicinal chemistry.

Advances in Cancer Research

  • 1st Edition
  • Volume 96
  • December 15, 2006
  • George F. Vande Woude + 3 more
  • English
  • Hardback
    9 7 8 - 0 - 1 2 - 0 0 6 6 9 6 - 4
  • eBook
    9 7 8 - 0 - 0 8 - 0 4 7 1 0 1 - 3
The Advances in Cancer Research series provides invaluable information on the exciting and fast-moving field of cancer research. This volume stands as the first ever thematic volume in the series, focusing on the topic of genomics in cancer drug development. The chapters included in this book represent the cutting-edge information in the field and span such topics as Mass Spectrometry: Uncovering the Cancer Proteome for Diagnostics; Biomarker Discovery in Epithelial Ovarian Cancer by Genomic Approaches; The Application of siRNA Technology to Cancer Biology Discovery; Ribozyme Technology for Cancer Gene Target Identification and Validation; Cancer Cell-Based Genomic and Small Molecule Screens; Tumour Antigens as Surrogate Markers and Targets for Therapy and Vaccines; Practices and Pitfalls of Mouse Cancer Models in Drug Discovery; Biomarker Assay Translation from Discovery to Clinical Studies in Cancer Drug Development – Quantification of Emerging Protein Biomarkers; Molecular Optical Imaging of Therapeutic Targets of Cancer; Cancer Drug Approval in the United States, Europe and Japan.

Target Validation in Drug Discovery

  • 1st Edition
  • September 22, 2006
  • Brian W. Metcalf + 1 more
  • English
  • Hardback
    9 7 8 - 0 - 1 2 - 3 6 9 3 9 3 - 8
  • eBook
    9 7 8 - 0 - 0 8 - 0 4 6 5 9 7 - 5
This work presents a comprehensive contemporary framework for approaching target validation in drug discovery. It begins with a detailed description of new enabling technologies, including aptamers, RNA interference, functional genomics, and proteomics. The next section looks at biologic drug development with in-depth discussion of lessons learned from such well-known cases as Erbitux, Herceptin, and Avastin. Additional targets known as "second generation" drugs, which can be identified when disease pathways are validated by biologics, present new possible small molecule therapeutics and serve as the focus of the final section of the book.

Drug Discovery

  • 1st Edition
  • December 15, 2005
  • Tamas Bartfai + 1 more
  • English
  • Paperback
    9 7 8 - 0 - 1 2 - 3 6 9 5 3 3 - 8
  • eBook
    9 7 8 - 0 - 0 8 - 0 9 1 9 2 3 - 2
Everyone expects something from the drug industry. Physicians and patients, investors, regulators and administrators all have an active interest. Everyone wants to know what makes drugs ‘work’ medically and economically. Why are drugs so expensive? Is it the drug companies or investors who demand high profits? What governs the pharmacoeconomics? Why are so few diseases treatable? Drug Discovery opens the windows and doors of the industry telling the story of drug development by using real stories from inside the process.

Novel Anticancer Agents

  • 1st Edition
  • December 13, 2005
  • Alex A. Adjei + 1 more
  • English
  • Hardback
    9 7 8 - 0 - 1 2 - 0 8 8 5 6 1 - 9
  • eBook
    9 7 8 - 0 - 0 8 - 0 5 3 7 7 5 - 7
Novel Anticancer Agents offers pertinent basic science information on strategies used for the rational design and discovery of novel anticancer agents, and, in addition, translational studies involving clinical trial design and execution with these novel, mostly cytostatic agents. This book covers basic science strategies that are being used in drug discovery and preclinical evaluation focused on novel molecular targets, as well as clinical trial methodology including clinical pharmacokinetics and imaging to address issues of efficacy evaluation of the new, relatively non-cytotoxic anticancer agents. At present, there is no book that provides such an integration of basic and clinical studies of novel anticancer agents, covering both drug discovery and translational research extensively.

Bioactive Lipids

  • 1st Edition
  • September 1, 2004
  • A Nicolaou + 1 more
  • English
  • Hardback
    9 7 8 - 0 - 9 5 3 1 9 4 9 - 7 - 1
In Bioactive lipids, Anna Nicolaou and George Kokotos have brought together an international team of authors to discuss the nomenclature, structures, biochemistry, pharmacology and recent developments in the main classes of bioactive lipids. These lipids are essential components of the cell membrane and play many dynamic roles in mediating and controlling a wide array of cellular activities including membrane structure and organization, metabolic and gene regulation, protein structure and function, energy production, and signalling pathways.The lipid interests of scientists in the pharmaceutical and food industries are converging as the broader significance of bioactive lipids is increasingly recognized. Lipids and lipid-metabolizing enzymes are targeted for the development of new drugs. Meanwhile, functional foods, nutraceuticals and supplements already have lipids as major active ingredients. The food industry will progress from simply using lipids as ingredients, to the formulation of products that influence the synthesis, metabolism and effects of bioactive lipids in the body. These advances in applied lipid biochemistry will build on the fundamental research of lipid scientists in universities worldwide, such as those scientists contributing to Bioactive lipids.